Jump To


  • Generic Name: gadobutrol
  • Brand Name: Gadavist
  • Drug Class: Gadolinium-Containing Contrast Agents
Last updated on MDtodate: 10/6/2022


The following serious adverse reactions are discussed elsewhere in labeling:

  • Nephrogenic Systemic Fibrosis (NSF).
  • Hypersensitivity reactions.

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

The adverse reactions described in this section reflect Gadavist exposure in 7,713 subjects (including 184 pediatric patients, ages 0 to 17 years) with the majority receiving the recommended dose. Approximately 52% of the subjects were male and the ethnic distribution was 62% Caucasian, 28% Asian, 5% Hispanic, 2.5% Black, and 2.5% patients of other ethnic groups. The average age was 56 years (range from 1 week to 93 years).

Overall, approximately 4% of subjects reported one or more adverse reactions during a follow-up period that ranged from 24 hours to 7 days after Gadavist administration.

Adverse reactions associated with the use of Gadavist were usually mild to moderate in severity and transient in nature.

Table 1 lists adverse reactions that occurred in ≥ 0.1% subjects who received Gadavist.

Table 1: Adverse Reactions

Reaction Rate (%)
Headache 1.7
Nausea 1.2
Dizziness 0.5
Dysgeusia 0.4
Feeling Hot 0.4
Injection site reactions 0.4
Vomiting 0.4
Rash (includes generalized, macular, papular, pruritic) 0.3
Erythema 0.2
Paresthesia 0.2
Pruritus (includes generalized) 0.2
Dyspnea 0.1
Urticaria 0.1


Adverse reactions that occurred with a frequency of < 0.1% in subjects who received Gadavist include: hypersensitivity/anaphylactic reaction, loss of consciousness, convulsion, parosmia, tachycardia, palpitation, dry mouth, malaise and feeling cold.

Postmarketing Experience

The following additional adverse reactions have been reported during postmarketing use of Gadavist. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

  • Cardiac arrest
  • Nephrogenic Systemic Fibrosis (NSF)
  • Hypersensitivity reactions (anaphylactic shock, circulatory collapse, respiratory arrest, pulmonary edema, bronchospasm, cyanosis, oropharyngeal swelling, laryngeal edema, blood pressure increased, chest pain, angioedema, conjunctivitis, hyperhidrosis, cough, sneezing, burning sensation, and pallor).
  • General Disorders and Administration Site Conditions: Adverse events with variable onset and duration have been reported after GBCA administration. These include fatigue, asthenia, pain syndromes, and heterogeneous clusters of symptoms in the neurological, cutaneous, and musculoskeletal systems.
  • Skin: Gadolinium associated plaques.



Read Next Article

PHP Code Snippets Powered By : XYZScripts.com